Hemostasis Flashcards

1
Q

Coagulation cascade diagram

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mechanisms in Medicine Coagulation Cascade Diagram

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

___ is the primary initiator of coagulation in vivo.

A

The extrinsic pathway is the primary initiator of coagulation in vivo.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Active complexes of the coagulation cascade

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The many roles of vWF

A
  • Stable binding partner of serum Factor VIII
  • Binding sites for collagen and a glycoprotein complex on platelets
  • Capable of ‘unwinding’ under sheer stress of bloodflow to be exposed and cut by ADAMTS13
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Thrombin activates platelets by ___.

A

Thrombin activates platelets by cleaving the thrombin receptor on their surface.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Activated platelet image

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Things that happen when platelets are activated (by thrombin, or ATP, or whatever)

A
  • Morphology change
  • Release arachadonic acid from membrane and metabolize to TxA2
  • Release of dense granule contents (including more ADP)
  • Release of alpha granule contents (containing proteins that contribute to hemostasis - platelet factor IV, thrombospondin, fibrinogen, and factor V)
  • Expose P-selectin (normally housed within alpha granules, part of degranulation)
  • Bring phosphatidylserine from the internal leaflet to the external leaflet
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Zymogens of the coagulation cascade are synthesized in ___.

A

Zymogens of the coagulation cascade are synthesized in the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Basic structure and cell biology of coagulation cascade zymogens

A
  • Signal peptide at N terminus
  • Serine protease active site at C terminus
  • Undergo crucial modifications at Golgi prior to release, including vitamin K-dependent carboxylation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

General role of protein cofactors in the coagulation cascade

A

Bind to platelet and endothelial cell membranes, where they serve as docking sites for zymogens and contribute importantly to the amplification that is essential for the rapid formation of the fibrin clot.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Coagulation in a glass tube

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

___ is not very important for coagulation ex-vivo, such as in a glass tube, but is crucial for in-vivo coagulation.

A

Factor IX is not very important for coagulation ex-vivo, such as in a glass tube, but is crucial for in-vivo coagulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Coagulation in humans

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

fibrinopeptides A and B

A

Released from fibrinogen when it is cleaved by thrombin to form fibrin. Measurement can be useful in evaluating patients with disseminated intravascular coagulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Factor XIIIa

A

Cross-links fibrin with covalent bonds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Tissue factor pathway inhibitor (TFPI)

A

Synthesized in endothelial cells and is present in plasma and platelets. blocks the extrinsic coagulation pathway after its initial activation by binding first to factor Xa, then jointly binding to and inactivating VIIa/TF complexes. This shuts down the extrinsic pathway after only small amounts of Xa and thrombin are generated.

This small amount of Xa and thrombin are sufficient to activate factor VIII and factor V, enabling the intrinsic pathway to provide a burst of procoagulant activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Antithrombin

A

Most important plasma protease inhibitor in regulating hemostasis. Binds to heparin or other glycoproteins on endothelial cells and here undergoes a conformational change to reveal a site that serves as a serine protease inhibitor.

It inactivates not only thrombin but also factors VIIa, IXa, Xa, and XIa as they are carried in the blood away from the developing thrombus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Protein C and Protein S

A

Work together. When activated by thrombin bound to thrombomodulin on the surface of normal endothelial cells, innactivate factors Va and VIIIa.

Undergo vitamin K–dependent carboxylation and share other structural features with factors VII, IX, X, and prothrombin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Platelet count

A

Platelets per microliter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Bleeding time

A

Make a controlled superficial incision on the forearm and monitoring the time that elapses before the bleeding stops.

As the straight vertical and diagonal lines show, in those with normal platelet function, the bleeding time is not prolonged unless the platelet count is less than 100,000 per microliter.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Requirements for aggregation vs agglutination

A

Aggregation requires calcium mobilization and the activation of the fibrinogen receptor, whereas agglu­tination merely depends on passive cross-linking of platelets mediated by bivalent binding of vWF to GPIb complexes and, therefore, occurs even with “dead” but intact platelets that have been fixed with formalin.

23
Q

Ristocetin

A

Antibiotic that facilitates vWF in plasma binding to normal platelets and inducing platelet agglutination

24
Q

In-vitro platelet-rich plasma tests

A
25
Q

In contrast to platelet function tests, ___ are routine tests done as a measure of numerous disease processes.

A

In contrast to platelet function tests, coagulation cascade function tests are routine tests done as a measure of numerous disease processes.

26
Q

Prothrombin Time (PT)

A

Assesses the extrinsic pathway of coagulation. Performed by adding recombinant tissue factor to the patient’s plasma, which normally clots after about 12 seconds.

A prolongation in the PT means that the patient has a functional deficiency of one or more of the clotting factors in the extrinsic pathway, specifically factors VII, X, V, prothrombin, or fibrinogen.

27
Q

Partial thromboplasatin time (PTT)

A

Assesses the intrinsic pathway of coagulation. Kaolin, a porous diatomaceous earth, is added to plasma, providing an artificial negatively charged contact surface that initiates the cascade by activating factor XII.

28
Q

Thrombin Time

A

Time required for a clot to form after the addition of exogenous thrombin to plasma. Assesses the amount and functionality of fibrinogen as well as the presence of thrombin inhibitors such as the anticoagulant heparin or breakdown products of fibrinogen and fibrin (fibrin degradation products) that interfere with fibrin formation.

29
Q

Interpreting PT, PTT, and TT together

A
30
Q

Once clotting deficiency has been narrowed down to a specific window, a functional diagnostic test may be done by. . .

A

. . . mixing patient plasma with standard plasma deficient in one particular clotting factor.

31
Q

In almost all of the inherited bleeding disorder, ___.

A

In almost all of the inherited bleeding disorder, only a single deficiency will be found

32
Q

If a patient has multiple functional deficiencies in the enzymes of coagulation, . . .

A

. . . it is likely to be an acquired condition due to liver disease, vitamin K deficiency, or disseminated intravascular coagulation.

33
Q

Vitamin K antagonists

A

Prevent carboxylation of factors VII, IX, X, and prothrombin, making them ineffective at promoting hemostasis.

The most commonly used vitamin K antagonist is warfarin. Patients treated with warfarin must be monitored closely with regular measurements of the PT to ensure that the degree of anticoagulation is within a therapeutic range. Warfin also has many food and drug interactions, which can be difficult for patients to manage.

Since the true mechanism of vitamin K antagonists is creating a functional deficiency in these enzymes, plasma transfusion may restore coagulability in an emergency.

34
Q

Heparin and heparin-like drugs

A

Polysaccharides, particularly heparin, activate the serine protease inhibitor antithrombin thereby inhibiting several steps in the coagulation cascade both in vivo and in vitro.

Heparin must be administered parenterally, but patients do not need to be monitored as closely as those on warfarin.

Unfractionated heparin occasionally causes a potentially serious complication, heparin-induced thrombocytopenia

35
Q

Heparin-induced thrombocytopenia

A

Autoantibody against a complex of the drug and platelet factor IV released from alpha granules.

This immune response activates platelets, commonly causing thrombocytopenia and, in some patients, life-threatening venous and/or arterial thrombosis

36
Q

Fibrinolytic drugs

A

Streptokinase and urokinase

More recently, recombinant tissue plasminogen activator has been shown to have superior efficacy

These therapies carry with them the risk of hemorrhage.

37
Q

Direct inhibitors

A

An advantage of these drugs is that they appear to have few interactions with other drugs or with foods and thus maintain patients in a therapeutic range of anticoagulation more consistently than does warfarin.

Argatroban, a high affinity thrombin inhibitor, is a major member of this family. Recently, an antibody reversal agent has been approved to mitigate bleeding due to dabigatran, a different direct thrombin inhibitor.

Direct oral factor Xa inhibitors also have been developed, including rivaroxaban, apixaban, and edoxaban, with reversal drugs on the way.

38
Q

X-V complex

A

Made by both the intrinsic and extrinsic pathways

Converts prothrombin to thrombin

39
Q

Thrombin

A

Among other things, converts the soluble molecule fibrinogen into a solid fibrin clot.

40
Q

Factors of the common pathway

A
41
Q

The extrinsic pathway utilizes ___ to activate factor X.

A

The extrinsic pathway (aka the PT pathway) utilizes factor VII to activate factor X.

42
Q

Intrinsic pathway order

A

Order of the intrinsic pathway (the PTT pathway)

Twelve

Eleven

Nine

Eight

Ten

43
Q

Clotting deficiencies - what matters clinically?

A
44
Q

Interpreting the results of a mixing study

A
  • If a substantial correction is noted after mixing patient and standard plasma, a deficiency is present
  • If there is no or little correction, an inhibitor is present
45
Q

Bleeding symtpoms in neonates

A
46
Q

Bleeding symptom tree

A
47
Q

Typical vWF panel

A
  1. Antigen test (quantify vWF)
  2. Functional test (usually ristocetin cofactor assay)
  3. Factor VIII activity
48
Q

How do you go about treating patients with acquired inhibition of clotting factors?

A

For low titer antibody, consider increasing dosage of factor.

For high titer antibody:

  1. Substitutes if available (Emcizumab)
  2. Porcine
  3. Recombinant Factor VIIa
  4. Purified prothrombin complex concentrate
  5. Induce tolerance through exposure therapy
49
Q

Patients with ___ are more likely to develop alloantibodies against clotting factors.

A

Patients with severe-grade hemophilia (<1% reference) are more likely to develop alloantibodies against clotting factors.

50
Q

What percentage baseline activity is considered to be rescued in a mixing study?

A

>40% reference

51
Q

What do you do if a hemophiliac patient comes with an acute bleed?

A
  1. If the factor deficiency is known, supplement with stock of that factor
  2. Emcizumab if Hemophilia A
  3. Fresh frozen plasma
52
Q

What is the relationship between primary and secondary hemostasis?

A

The phospholipid surface created by primary hemostasis provides the negatively-charged platform for activation of secondary hemostasis

53
Q

The most common mutation in factor VIII is ___.

The most common mutation in factor IX is ___.

A

The most common mutation in factor VIII is an inversion.

The most common mutation in factor IX is a missense mutation.

Thus, factor VIII mutations tend to be more ablative and are more likely to develop alloantibodies against factor VIII.